ABG Oxidative Stress Study Protocol-1

August 7, 2014 updated by: Access Business Group

Proof of Concept Study to Evaluate the Effect of Oxidative Stress Response of Plant Concentrate Blends in Healthy Men

This is a proof of concept study that evaluates the response to oxidative stress in healthy men after taking plant concentrates.

Study Overview

Detailed Description

Sustained oxidative stress may cause hypertension, insulin resistance, metabolic syndrome, cardiovascular disease and other chronic conditions. Diets rich in natural antioxidants is associated with protective effects on the investigators health. The strategy to prevent chronic disease development and in making up the nutritional gap in the investigators diet has shifted from vitamins and minerals supplementation to whole foods and whole food products.

The objectives is to evaluate the effect of oxidative stress response of plant concentrate blends. Also, we'll confirm that vitamins, minerals and plant concentrates will not influence the biomarker expression that were monitored in the oxidative stress biomarkers. Lastly, collecting additional information on whether blends of plant concentrate have other potential health benefits.

This study will test the dose-response of blends of plant concentrates. Healthy men (n=60) with low fruit and vegetable intake will participate in a 32 day or 46 days. Each treatment duration lasts 14 days. Microarray assay and real time-polymerase chain reaction will be performed.Genes associated with oxidative stress will me monitored. The outcome of this study will help us understand how to design and develop future antioxidant related products.

Study Type

Interventional

Enrollment (Actual)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • Buena Park, California, United States, 90620
        • Southbay Pharma Research
      • Buena Park, California, United States, 90620
        • Quality of Life

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

45 years to 65 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Healthy adult men between 45-65 yr old with low fruit and vegetable intake
  • Individual with low fruit and vegetable intake and consuming fewer than 12 items found on the Recommended Foods Check (RFC) (AppendixI) per week. (score <12 pts)
  • Individuals with screening blood and urine laboratory values within 20% of normal range indicated in the lab report (Appendix IV)
  • Individual should be judged to be in good general health on the basis of an interview and abbreviated physical exam.
  • Individual understands the procedures and agrees to participate in the study.
  • Individual is willing to maintain their exercise habits and dietary pattern throughout the duration of the trial.
  • Individual is willing to consume a diet or drink devoid of high content of quercetin (e.g. apple and onions), rosemary, turmeric, Holy basil, wasabi, broccoli seeds, and licorice thought the duration of the trial.
  • Individual is able and willing to provide written informed consent and confidentiality agreement.

Exclusion Criteria:

  • Use of dietary supplements within one week of DAy 1. Supplements include any vitamins, minerals, and herbal products, including herbal drink.
  • Presence of, or clinical significant history of, cancer, cardiovascular, endocrine, kidney, liver, lung, gastrointestinal, metabolic disorder, absorption disorder such as Celiae or Crohn's disease and/or any other chronic health condition such as diabetes identified from the finding of the interview.
  • Presence of cardiovascular disease and hypertension with inconsistent medication regimen, unstable conditions, and without proper physician's supervision identified from the findings fo the interview.
  • Individual who use medicines such as statins (e.g. simvastatin, fluvastatin), NSAIDS including aspirin, nitric oxide *eNOS) activators or inhibitors (e.g. selegiline, Viagra), and angiotensin II receptor blocker (e.g. Telmisartan (blood pressure)), and take any of these medications within 10 hours prior to the blood and urine sample collection.
  • Individuals who eat spicy food (e.g. capsaicin from chili pepper) and drink coffee and tea including herbal teas within 10 hours prior to the blood and urine sample collection.
  • Participation in another clinical trial within 30 days of enrollment into the study.
  • History of current abuse of nicotine, drugs or alcohol, or intake >3 alcoholic beverages per day
  • Have known allergy to the ingredients in the tested samples such as quercetin, rosemary, turmeric, Holy basil, wasabi, broccoli seeds, and licorice.
  • Any condition that the principal Investigator believes amy put the subject under risk.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: PREVENTION
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: DOUBLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Plant concentrate A
Plant concentrate A containing Rosemary:Quercetin:Turmeric 5:3:1 Low dose (300 mg) to high dose (600 mg)
Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
Experimental: Plant concentrate B
Plant concentrate B containing Holy Basil: Wasabi: Broccoli 5:5:1 Low dose (300 mg) to high dose (600 mg)
Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
Experimental: Plant concentrate C
Plant concentrate C containing Holy Basil:Rosemary:Broccoli seed:Turmeric 2:2:1:1 Low dose (300 mg) to High dose (600 mg)
Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
Experimental: Plant concentrate D
Plant concentrate D containing Rosemary:Licorice:Turmeric 1:1:1 Low dose (300 mg) to High dose (600 mg)
Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in urine 8-isoprostane
Time Frame: Day 1, 15
Change in antioxidant biomarker from baseline to day 15
Day 1, 15

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in erythrocyte Superoxide Dismutase
Time Frame: 1, 15
Change in antioxidant biomarker from baseline to day 15
1, 15
Change in plasma malondialdehyde
Time Frame: Day 1, 15
Change in antioxidant biomarker from baseline to day 15
Day 1, 15
Plasma hemoxygenase-1
Time Frame: Day 1, 15
Change in antioxidant biomarker from baseline to day 15
Day 1, 15
Erythrocyte glutathione peroxidase
Time Frame: Day 1, 15
Change in antioxidant biomarker from baseline to day 15
Day 1, 15

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2012

Primary Completion (Actual)

November 1, 2012

Study Completion (Actual)

December 1, 2013

Study Registration Dates

First Submitted

August 7, 2014

First Submitted That Met QC Criteria

August 7, 2014

First Posted (Estimate)

August 11, 2014

Study Record Updates

Last Update Posted (Estimate)

August 11, 2014

Last Update Submitted That Met QC Criteria

August 7, 2014

Last Verified

August 1, 2014

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • ABG AOX-1

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on Plant concentrate A

3
Subscribe